Discovery of new molecular entities able to strongly interfere with Hsp90 C-terminal domain

Area of Science:

• Molecular Biology
• Oncology
• Drug Discovery

Background:

• Heat shock protein 90 (Hsp90) is a molecular chaperone crucial for cancer cell proliferation, survival, invasion, and angiogenesis.
• Traditional Hsp90 N-terminal inhibitors have faced challenges due to the induction of a detrimental heat shock response (HSR).
• Selective inhibition of the Hsp90 C-terminal domain presents a promising alternative anti-cancer strategy by avoiding HSR.

Purpose of the Study:

• To identify and characterize novel, potent inhibitors targeting the Hsp90 C-terminal domain.
• To develop anti-cancer therapeutics that circumvent the limitations of N-terminal Hsp90 inhibitors.
• To find drug candidates that induce cancer cell death without eliciting the heat shock response.

Main Methods:

• Utilized an orthogonal screening approach to identify Hsp90 C-terminal inhibitors.
• Evaluated the efficacy of identified inhibitors in inducing cancer cell death.
• Assessed the impact of inhibitors on Hsp90 client oncoproteins and the heat shock response.

Main Results:

• Discovered two new potent inhibitors targeting the Hsp90 C-terminal domain.
• Demonstrated that these inhibitors induce cancer cell death.
• Showed significant down-regulation of Hsp90 client oncoproteins without triggering the heat shock response.
• Overcame the challenge of limited structural information for C-terminal Hsp90 inhibitors.

Conclusions:

• The newly identified Hsp90 C-terminal inhibitors represent a promising new avenue for anti-cancer drug development.
• Selective C-terminal inhibition offers a viable strategy to avoid HSR and enhance therapeutic efficacy.
• Further investigation into these compounds could lead to effective cancer treatments.